• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Market characteristics o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Indication o Market segments o Comparison by Indication o Diabetic neuropathy - Market size and forecast 2019-2024 o Chemotherapy-induced neuropathy pain - Market size and forecast 2019-2024 o Postherpetic neuralgia - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by indication • Market Segmentation by drug class o Calcium channel alpha 2-delta ligands o Serotonin-norepinephrine reuptake inhibitors (SNRIs) o TCAs o Opioid analgesics o Others • Customer landscape o Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o South America - Market size and forecast 2019-2024 o MEA - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Abbott Laboratories o Assertio Therapeutics Inc. o AstraZeneca Plc o Baxter International Inc. o Dr Reddy's Laboratories o Eli Lilly and Co. o Endo International Plc o Johnson & Johnson o Pfizer Inc. o Sanofi • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Other1 - Market share 2019-2024 (%) • 22: Comparison by Other1 • 23: Diabetic neuropathy - Market size and forecast 2019-2024 ($ million) • 24: Diabetic neuropathy - Year-over-year growth 2019-2024 (%) • 25: Chemotherapy-induced neuropathy pain - Market size and forecast 2019-2024 ($ million) • 26: Chemotherapy-induced neuropathy pain - Year-over-year growth 2019-2024 (%) • 27: Postherpetic neuralgia - Market size and forecast 2019-2024 ($ million) • 28: Postherpetic neuralgia - Year-over-year growth 2019-2024 (%) • 29: Others - Market size and forecast 2019-2024 ($ million) • 30: Others - Year-over-year growth 2019-2024 (%) • 31: Market opportunity by Other1 • 32: Customer landscape • 33: Market share by geography 2019-2024 (%) • 34: Geographic comparison • 35: North America - Market size and forecast 2019-2024 ($ million) • 36: North America - Year-over-year growth 2019-2024 (%) • 37: Europe - Market size and forecast 2019-2024 ($ million) • 38: Europe - Year-over-year growth 2019-2024 (%) • 39: APAC - Market size and forecast 2019-2024 ($ million) • 40: APAC - Year-over-year growth 2019-2024 (%) • 41: South America - Market size and forecast 2019-2024 ($ million) • 42: South America - Year-over-year growth 2019-2024 (%) • 43: MEA - Market size and forecast 2019-2024 ($ million) • 44: MEA - Year-over-year growth 2019-2024 (%) • 45: Key leading countries • 46: Market opportunity by geography ($ million) • 47: Impact of drivers and challenges • 48: Vendor landscape • 49: Landscape disruption • 50: Industry risks • 51: Vendors covered • 52: Market positioning of vendors • 53: Abbott Laboratories - Overview • 54: Abbott Laboratories - Business segments • 55: Abbott Laboratories - Key offerings • 56: Abbott Laboratories - Key customers • 57: Abbott Laboratories - Segment focus • 58: Assertio Therapeutics Inc. - Overview • 59: Assertio Therapeutics Inc. - Business segments • 60: Assertio Therapeutics Inc. - Key offerings • 61: Assertio Therapeutics Inc. - Key customers • 62: Assertio Therapeutics Inc. - Segment focus • 63: AstraZeneca Plc - Overview • 64: AstraZeneca Plc - Business segments • 65: AstraZeneca Plc - Key offerings • 66: AstraZeneca Plc - Key customers • 67: AstraZeneca Plc - Segment focus • 68: Baxter International Inc. - Overview • 69: Baxter International Inc. - Business segments • 70: Baxter International Inc. - Key offerings • 71: Baxter International Inc. - Key customers • 72: Baxter International Inc. - Segment focus • 73: Eli Lilly and Co. - Overview • 74: Eli Lilly and Co. - Business segments • 75: Eli Lilly and Co. - Key offerings • 76: Eli Lilly and Co. - Key customers • 77: Eli Lilly and Co. - Segment focus • 78: Endo International Plc - Overview • 79: Endo International Plc - Business segments • 80: Endo International Plc - Key offerings • 81: Endo International Plc - Key customers • 82: Endo International Plc - Segment focus • 83: Johnson & Johnson - Overview • 84: Johnson & Johnson - Business segments • 85: Johnson & Johnson - Key offerings • 86: Johnson & Johnson - Key customers • 87: Johnson & Johnson - Segment focus • 88: Pfizer Inc. - Overview • 89: Pfizer Inc. - Business segments • 90: Pfizer Inc. - Key offerings • 91: Pfizer Inc. - Key customers • 92: Pfizer Inc. - Segment focus • 93: Sanofi - Overview • 94: Sanofi - Business segments • 95: Sanofi - Key offerings • 96: Sanofi - Key customers • 97: Sanofi - Segment focus • 98: Currency conversion rates for US$ • 99: Research Methodology • 100: Validation techniques employed for market sizing • 101: Information sources • 102: List of abbreviations

Abbott Laboratories, Assertio Therapeutics Inc. , AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., Sanofi